Overall, BC-3781 was confirmed to have largely 'no interaction', neither
antagonism nor synergy, when combined with other antibiotics against Gram-
positive or Gram-negative organisms, including those with important resistance
phenotypes (e.g. MRSA and ESBL) suggesting that there is no potential issue for
combination therapy when Gram-negative coverage is necessary.
Accumulation of the Pleuromutilin Antibiotic BC-3781 in Murine Macrophages and
Effect of Lung Surfactant on the BC3781 In Vitro Activity
S. Paukner, K. Krause, A. Gruss, T. Keepers, M. Gomez, A. Bischinger, D.B.
Strickmann, Z. Ivezic-Schoenfeld
Poster # A-011
Overall, BC-3781 accumulated in murine macrophages at clinically relevant
extraceulluar concentrations and the antimicrobial potency of BC-3781 was
unaffected by lung surfactant. Together with the high tissue penetration into
the lung, these data support the investigation of BC-3781 in bacterial
In Vitro Activity Of The Novel Pleuromutilin BC-3781 Tested Against Bacterial
Pathogens Causing Sexually Transmitted Diseases (STD)
S. Paukner, A. Gruss, T. R. Fritsche, Z. Ivezic-Schoenfeld, R. N. Jones
Poster # E-1183
Overall, BC-3781 displayed potent activity against the most relevant bacterial
pathogens causing STD warranting further investigations on the potential of BC-
3781 in this indication.
About Nabriva Therapeutics
Nabriva Therapeutics is a biotechnology company focused on developing a new
class of antibiotics for the treatment of serious infections caused by resistant
pathogens and sexually transmitted diseases. Nabriva's lead product BC-3781 is a
broad spectrum agent being developed for the treatment of serious skin
infections and community-acquired bacterial pneumonia (CABP) caused by
S. aureus, S. pneumoniae, H. influenzae, M. pneumoniae, L. pneumophila and
other bacteria, including drug resistant strains such as methicillin-resistant
S. aureus (MRSA) and vancomycin-resistant E. faecium. Proof of concept for the
systemic use of BC-3781 in humans was achieved in a Phase 2 trial in patients
with acute bacterial skin and skin structure infections (ABSSSI). BC-3781 is a
Phase 3 ready product for ABSSSI and CABP indications. In addition, BC-7013, a
topical treatment for dermatological diseases has completed Phase 1 trials. In
preclinical studies, the company is developing extended spectrum pleuromutilins
(ESPs) with broad activity against both Gram-positive and Gram-negative
bacterial infections. In particular, the ESPs are focused on the high unmet
medical need to treat Urinary Tract Infections and complicated Intra Abdominal
Infections, plus other serious bacterial infections.
Nabriva Therapeutics has a proven track record in world-class medicinal
chemistry, clinical expertise, a seasoned management team and solid IP.
Nabriva's current shareholders include: Phase4 Ventures, HBM Partners, Wellcome
Trust, Global Life Science Ventures, Novartis Venture Fund and Sandoz. Nabriva
Therapeutics is located in Vienna, Austria.
For more information on Nabriva please visit www.nabriva.com.
NABRIVA THERAPEUTICS AG MC SERVICES
Ralf Schmid Raimund Gabriel
Chief Executive Officer Managing Partner
T +43 (0)1 740 930 T +49 89 210 228-30
Press Release PDF:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Nabriva Therapeutics AG via Thomson Reuters ONE